Hepatic encephalopathy in liver cirrhosis: Pathogenesis, diagnosis and management

Drugs

Volumn 60, Issue 6, 2000, Pages 1353-1370

  Gerber, Tilman ^a   Schomerus, Haus ^a  

^a Medical Clinic II   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXOGLUTARIC ACID; 4 AMINOBUTYRIC ACID; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMMONIA; ANTIBIOTIC AGENT; BENZOIC ACID; BRANCHED CHAIN AMINO ACID; GLUTAMIC ACID; LACTULOSE; MEDIUM CHAIN FATTY ACID; NEUROLEPTIC AGENT; NEUROTOXIN; NEUROTRANSMITTER; NEUROTRANSMITTER RECEPTOR; ORNITHINE ASPARTATE; PHENOL DERIVATIVE; SEROTONIN; SHORT CHAIN FATTY ACID; THIOL DERIVATIVE;

ANTIBIOTIC THERAPY; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID EXAMINATION; COGNITIVE DEFECT; DETOXIFICATION; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRUG INDUCED DISEASE; ELECTROPHYSIOLOGY; HELICOBACTER PYLORI; HEPATIC ENCEPHALOPATHY; HUMAN; LABORATORY TEST; LIVER CIRRHOSIS; NEUROPSYCHOLOGICAL TEST; PATHOGENESIS; PORTOSYSTEMIC ANASTOMOSIS; PROTEIN RESTRICTION; PSYCHOMETRY; REVIEW; RISK FACTOR; THEORY;

ANTI-BACTERIAL AGENTS; ANTIPSYCHOTIC AGENTS; BLOOD-BRAIN BARRIER; DIAGNOSIS, DIFFERENTIAL; DIET; DISACCHARIDES; ELECTROPHYSIOLOGY; HEPATIC ENCEPHALOPATHY; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; NEUROPSYCHOLOGICAL TESTS; NEUROTRANSMITTER AGENTS; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC;

EID: 0034522210     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200060060-00008     Document Type: Review

References (134)

1. The disease picture of hepatic encephalopathy
2. Ammonia: Key factor in the pathogenesis of hepatic encephalopathy
3. Ammonia detoxication and glutamine metabolism in severe liver disease and its role in the pathogenesis of hepatic encephalopathy
4. Neuronal effects of ammonia
5. The effect of acute ammonia intoxication on cerebral metabolism in rats with portocaval shunts
6. Proton magnetic resonance spectroscopy studies on human brain myo-inositol in hypo-osmolarity and hepatic encephalopathy
7. Studies of the blood ammonia in liver disease: Its diagnostic, prognostic and therapeutic significance
8. Arterial ammonia levels in haptic encephalopathy: Utility in diagnosis
9. Synergism between mecaptans and ammonia or fatty acids in the production of coma: A possible role for mercaptans in the pathogenesis of hepatic encephalopathy
10. The role of methanethiol in the pathogenesis of hepatic encephalopathy
11. Encephalopathic effect of phenol in rats
12. Hepatogene encephalopathie
13. Potential toxins of acute liver failure and their effects on blood-brain barrier permeability
14. Increased bloodbrain transfer in a rabbit model of acute liver failure
15. Hepatic encephalopathy and cerebral edema
16. Regional blood-brain barrier permeability to amino acids after portocaval anastomosis
17. Brain microvessels take up large neutral amino acids in exchange for glutamine: Cooperative role of Na+-dependent and Na+-independent systems
18. False neurotransmitter in hepatic failure
19. The role of plasma amino acid in hepatic encephalopathy
20. Hyperammonemia, plasma amino acid imbalance and blood-brain amino acid transport: A unified theory of portal-systemic encephalopathy
21. Urinary and serum octopamine in patients with portosystemic encephalopathy
22. Experimental hepatic encephalopathy: Changes in the binding of gamma amonibutyric acid
23. Mechanism of the excessive sedative response of cirrhotics to benzodiazepines: Model experiments with triazolam
24. Evidence for the role of ammonia in the intercerebral transfer and metabolism of tryptophan
25. Can hepatic coma be caused by a reduction of brain noradrenaline or dopamine?
26. Circulating noradrenaline and central haemodynamics in patients with cirrhosis
27. Overt hepatic encephalopathy precipitated by zinc deficiency
28. Manganese and chronic hepatic encephalopathy
29. Latent portasystemic encephalopathy: I. Nature of cerebral functional defects and their effect on fitness to drive
30. High prevalence of sleep disturbance in cirrhosis
31. The disorder of movement in the more common varieties of liver disease
32. Neuro-psychiatric complications following chlorothiazide therapy in patients with hepatic cirrhosis: Possible relation to hypokalaemia
33. Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: Results of a prospective controlled study
34. Transjugular intrahepatic portosystemic shunt and hepatic encephalopathy
35. The role of TIPS for the treatment of portal hypertension: Effects and efficacy
36. Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: Clinical, laboratory, psychometric and electroencephalographic investigations
37. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunts: Incidence and risk factors
38. The first decade of the transjugular intrahepatic portosystemic shunt: State of the art
39. Hyperammonaemia and helicobacter pylori
40. The influence of helicobacter pylorion protein-induced hyperammonaemia in cirrhotic patients without hepatic encephalopathy
41. Helicobacter pylori and liver: Any relationship?
42. Helicobacter pylori, hyperammonaemia and subclinical portosystemic encephalopathy: Effects of eradication
43. Hepatic encephalopathy: Neuropsychological and neurophysiological diagnosis
44. Subclinical hepatic encephalopathy: Detection, prevalence and relationship to nitrogen metabolism
45. The diagnosis and prevalence of subclinical hepatic encephalopathy in apparently ambulant non-shunted patients with cirrhosis
46. Psychometric test and latent portosystemic encephalopathy
47. Somatosensory evoked potentials and number connection test in the detection of subclinical hepatic encephalopathy
48. Neuropsychological aspects of portal-systemic encephalopathy
49. Validity of the trailmaking test as an indicator of organic brain damage
50. Trailmaking and number connection test in the assessment of mental state in portal systemic encephalopathy
51. Differences in neuropsychological test performance associated with age, education and sex
52. Visual evokes potentials: A tool in the diagnosis of hepatic encephalopathy
53. The electroencephalograph in liver disease
54. Hepatic encephalopathy: Comparative study of EEG abnormalities, neuropsychic disturbances and blood ammonia
55. Objective measurement of hepatic encephalopathy by means of automated EEG analysis
56. Subclinical hepatic encephalopathy: The diagnostic value of evoked potentials
57. Visual evoked potentials: Current perspectives
58. Flash visual evoked responses in the early encephalopathy of chronic liver disease
59. Visual event-related P300 potentials in early portosystemic encephalopathy
60. The auditory P300 event-related potential: An objective marker of the encephalopathy of chronic liver disease
61. Auditory event-related cerebral potentials (P300) in hepatic encephalopathy: Topographic distribution and correlation with clinical and psychometric assessment
62. Cerebral changes in hepatic encephalopathy
63. Prevalence of brain atrophy in liver cirrhosis patients with chronic persistent encephalopathy: Evaluation by computed tomography
64. The basal ganglia and portal systemic encephalopathy
65. Correlations between neuropsychological test performance and brain metabolism in cirrhotics
66. Cerebral benzodiazepine receptor binding in vivo in patients with recurrent hepatic encephalopathy
67. Brain magnetic resonance imaging in liver cirrhosis patients with encephalopathy
68. Neuropsychiatric profile and hyperintensive globus pallidus on T1-weighted magnetic resonance images in liver cirrhosis
69. Cerebral glucose metabolism and hyperintense on T1-weighted magnetic resonance images on globus pallidus in patients with liver cirrhosis
70. MRI findings in chronic hepatic encephalopathy depend on portosystemic shunt: Results of a controlled prospective clinical investigation
71. Bright basal ganglia in T1-weighted magnetic resonance images are frequent in patients with portal vein thrombosis without liver cirrhosis and not suggestive of hepatic encephalopathy
72. Proton magnetic resonance: The new gold standard for diagnosis of clinical and subclinical hepatic encephalopathy
73. Multinuclear NMR spectroscopy studies on NH4Cl-induced metabolic alterations and detoxification processes in primary astrocytes and glioma cells
74. Dietary management of portal-systemic encephalopathy
75. Vegetable versus animal protein diet in cirrhotic patients with chronic encephalopathy: A randomized cross-over comparison
76. Treatment of chronic portal systemic encephalopathy with vegetable and animal protein diets
77. Effect of vegetable and animal protein diets in chronic hepatic encephalopathy
78. Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy: A meta-analysis
79. Branched chain amino acids in the treatment of latent portosystemic encephalopathy
80. Long-term treatment of latent portosystemic encephalopathy with branched-chain amino acids
81. Comparison of dietary protein with an oral, branched chain-enriched amino acid supplement in chronic portal-systemic encephalopathy: A randomized controlled trial
82. Lactulose enemas
83. Acidifying enemas (lactilol and lactulose) vs. nonacidifying enemas (tap water) to treat acute portalsystemic encephalopathy: A double-blind randomized trial
84. Lactulose: A multifaceted substance
85. Treatment of chronic portalsystemic encephalopathy with lactulose
86. Clinical trials of nonabsorbable disaccharide therapy in hepatic encephalopathy
87. Lactulose and combination therapy of hepatic encephalopathy: The role of the intestinal microflora
88. Lactilol or lactulose in the treatment of chronic hepatic encephalopathy: Results of a meta-analysis
89. Lactilol versus lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: A double-blind randomised trial
90. Lactilol in treatment of chronic hepatic encephalopathy: A meta-analysis
91. Treatment of chronic portal systemic encephalopathy with lactose in lactase-deficient patients
92. Beneficial effect of carbohydrate maldigestion induced by a disaccharidase inhibitor (AO-128) in the treatment of chronic portal-systemic encephalopathy: A double-blind, randomized controlled trial
93. Comparison of lactulose and neomycin in the treatment of chronic portalsystemic encephalopathy
94. Ammonia and glutamine metabolism of the intestine: The effect of lactulose and neomycin
95. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy: A controlled double-blind clinical trial
96. Deafness complicating antibiotic therapy of hepatic encephalopathy
97. Treatment of hepatic encephalopathy with metronidazole
98. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy
99. Successful use of vancomycin hydrochloride in the treatment of lactulose-resistent chronic hepatic encephalopathy
100. Could an endogenous benzodiazepine ligand contribute to hepatic encephalopathy?
101. Brain concentrations of benzodiazepines are elevated in an animal model of hepatic encephalopathy
102. Elevated brain concentrations of 1,4-bezodiazepines in fulminant hepatic failure
103. Endogenous benzodiazepine receptor ligands in human and animal hepatic encephalopathy
104. Increased availability of central benzodiazepine receptors in patients with chronic hepatic encephalopathy and alcohol relate cirrhosis
105. Flumazenil therapy for hepatic encephalopathy in cirrhotic patients: A doubleblind pragmatic randomized placebo study
106. Effect of flumazenil on the electroencephalogram of patients with portosystemic encephalopathy: Results of a double-blind randomized, placebo-controlled multicenter trial
107. Flumazenil in cirrhotic patients in hepatic coma. A randomized doubleblind placebo controlled crossover trial
108. Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: An Italian multicentre double-blind placebo-controlled crossover study
109. Treatment of cirrhotic hepatic encephalopathy with L-dopa: A controlled trial
110. Successful use of bromocriptine in the treatment of hepatic encephalopathy
111. Treatment of chronic portal systemic encephalopathy with bromocriptine
112. Neuropharmacologic modulation of hepatic encephalopathy: Experimental and clinical data
113. Opoid receptor ligands in human hepatic encephalopathy
114. On therapy of hepatic coma with metabolites of the urea cycle, glutamate and alphaketoglutarate
115. Effects of ornithine aspartate on plasma ammonia and plasma amino acids in patients with cirrhosis: A double-blind, randomized study using a four-fold crossover design
116. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: Results of a placebo-controlled, double-blind study
117. Omithine-L-aspartate in the treatment of hyperammonemia and hepatic encephalopathy
118. A new therapy for portal systemic encephalopathy
119. Sodium benzoate in the treatment of acute hepatic encephalopathy: A double-blind randomized trial
120. Treatment of hepatic encephalopathy
121. The effect of maintenance zinc treatment in liver cirrhosis with hepatic encephalopathy
122. Prognostic value of plasma zinc value in cirrhotic patients
123. Liver transplantation, AASLD Practice Guidelines
124. MR imaging and (1) H spectroscopy of brain metabolites in hepatic encephalopathy: Time-course of renormalization after liver transplantation
125. Surgical treatment of severe postshunt hepatic encephalopathy
126. Manganese in health and disease
127. Hyperintense globus pallidus on T1-weighted MRI in cirrhotic patients associated with severe of liver failure
128. The reducing stent: Treatment for transjugular intrahepatic portosystemic shunt-induced refractory hepatic encephalopathy and liver failure
129. Lactobacillus acidophilus in treatment of hepatic encephalopathy
130. Treatment of hepatic encephalopathy by alterations of intestinal flora and Lactobacillus acidophilus
131. Long-term effects of enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy